Loading...
XJPX
2929
Market cap139mUSD
Dec 05, Last price  
749.00JPY
1D
-0.27%
1Q
-22.70%
Jan 2017
79.62%
IPO
31.40%
Name

Pharma Foods International Co Ltd

Chart & Performance

D1W1MN
XJPX:2929 chart
P/E
6.75
P/S
0.35
EPS
111.01
Div Yield, %
3.34%
Shrs. gr., 5y
-0.42%
Rev. gr., 5y
42.62%
Revenues
62.15b
-9.37%
810,836,000734,098,000959,103,0001,006,661,0001,225,029,0001,524,506,0001,614,558,0002,165,708,0003,460,766,0004,722,596,0007,943,262,00010,532,834,00015,353,384,00046,752,000,00060,185,000,00068,572,000,00062,147,000,000
Net income
3.21b
+4.02%
-455,017,000-207,576,00015,246,000-46,602,00060,034,000269,346,0008,831,000-187,887,00025,896,000101,310,000313,661,000499,849,000690,000,0003,841,000,000-374,000,0003,081,000,0003,205,000,000
CFO
5.49b
-10.43%
-139,662,000-129,344,000-32,823,000-18,782,000179,261,00016,763,000-218,500,000-242,112,000-35,298,000233,853,000415,543,00090,655,000-547,064,0005,938,000,000-6,065,000,0006,125,000,0005,486,000,000
Dividend
Jan 29, 202612.5 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. Its products include Pharma-GABA, Bonepep, Ovopron (egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg, as well as iHA, a substance that stimulates secretion of hyaluronic acid. Pharma Foods International Co., Ltd. has licensing agreement with Mitsubishi Tanabe Pharma Corporation for a new therapeutic antibody to treat autoimmune diseases. Pharma Foods International Co., Ltd. was founded in 1997 and is based in Kyoto, Japan.
IPO date
Jun 12, 2006
Employees
624
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT